Business · 22/06/2011Updated: 10/17/2026 · 1 min read
National Institutes of Health Grants Exclusive Patent License for Ulipristal Acetate Treatment of Uterine Fibroids
Summary
The National Institutes of Health is considering granting an exclusive patent license to PregLem SA to practice ulipristal acetate for treating symptomatic uterine fibroids, with the rights assigned to the US government and Laboratoire HRA Pharma.